Dr. Srivastava serves on the advisory boards for Allergan, Bausch & Lomb, and Alimera.
Juvenile Idiopathic Arthritis
Development of a vision-related quality of life instrument for children ages 8–18 years for use in juvenile idiopathic arthritis–associated uveitis
Article first published online: 29 AUG 2011
Copyright © 2011 by the American College of Rheumatology
Arthritis Care & Research
Volume 63, Issue 9, pages 1254–1261, September 2011
How to Cite
Angeles-Han, S. T., Griffin, K. W., Harrison, M. J., Lehman, T. J. A., Leong, T., Robb, R. R., Shainberg, M., Ponder, L., Lenhart, P., Hutchinson, A., Srivastava, S. K., Prahalad, S., Lambert, S. R. and Drews-Botsch, C. (2011), Development of a vision-related quality of life instrument for children ages 8–18 years for use in juvenile idiopathic arthritis–associated uveitis. Arthritis Care Res, 63: 1254–1261. doi: 10.1002/acr.20524
- Issue published online: 29 AUG 2011
- Article first published online: 29 AUG 2011
- Accepted manuscript online: 15 JUN 2011 10:14AM EST
- Manuscript Accepted: 2 JUN 2011
- Manuscript Received: 28 DEC 2010
- Arthritis Foundation New York Chapter
- Weill Cornell Medical College Clinical and Translational Science Center. Grant Number: UL1RR024996
- Research to Prevent Blindness
- Emory Egleston Children's Research Center
- Knights Templar Eye Foundation
To determine the validity and reliability of a novel questionnaire to measure vision-related quality of life (VRQOL) in children ages 8–18 years for use in juvenile idiopathic arthritis (JIA)–associated uveitis: the Effects of Youngsters' Eyesight on Quality of Life (EYE-Q).
Several steps validated the EYE-Q. We interviewed experts and children on how vision affects a child's activities. We developed new items and selected relevant items from existing instruments. We administered initial versions of the EYE-Q to normal-sighted children and those with JIA-associated uveitis. For this study, children with various (or no) ocular conditions were recruited from a clinical population. Visual acuity and contrast sensitivity were performed, and the EYE-Q and Pediatric Quality of Life Inventory (PedsQL) were administered. The EYE-Q was repeated 10 days later. Patients, parents, and physicians rated vision severity.
Of 120 patients, 48% were female, 46.7% had no visual impairment, and 53.3% had bilateral eye involvement. The mean age was 11.3 years. There were significant differences in the measures based on visual acuity (P < 0.001). Children with more severe visual acuity and bilateral eye involvement had worse EYE-Q scores (P < 0.001). There were significant associations between the EYE-Q and PedsQL (r = 0.375), repeat EYE-Q (r = 0.864), and clinical measures of ocular disease (r = −0.620).
Our study provides evidence of the validity and reliability of the EYE-Q in the measurement of VRQOL. The EYE-Q may complement clinical measures of visual impairment and overall QOL and become an important tool in the assessment of QOL in JIA-associated uveitis.